MedTrace Logo

The Analgesic Efficacy and Safety of Flurbiprofen Patch in Patients With Herpes Zoster

NCT07370402 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 750

Last updated 2026-01-27

No results posted yet for this study

Summary

Herpes zoster (HZ) is characterized by a painful dermatomal rash and significantly affects quality of life, with acute pain increasing the risk of postherpetic neuralgia. Although early antiviral therapy limits viral replication, its analgesic effect is insufficient, and many patients experience inadequate relief despite stepwise use of non-opioids and opioids. Topical NSAIDs offer a promising alternative by delivering localized analgesia with reduced systemic exposure. Therefore, investigators hypothesize that flurbiprofen patch may effectively reduce the severity of HZ pain without significantly increasing adverse events.

Conditions

  • Herpes Zoster
  • Pain

Interventions

DRUG

Flurbiprofen patch combined with conventional therapy group

In the flurbiprofen patch combined with conventional therapy group, apply the patch to the painful point near the herpes lesion. Use one patch per day, twice a day. In addition, the group will contain conventional treatment for HZ, except flurbiprofen patch, including opioids, antiviral drugs and so on.

DRUG

Conventional therapy group

In the conventional therapy group, treatments will include opioids, antiviral drugs and so on.

Sponsors & Collaborators

  • Beijing Tiantan Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-15
Primary Completion
2027-09-30
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07370402 on ClinicalTrials.gov